Abstract
Bortezomib (PS-341, Velcade, Millennium Pharmaceuticals, Cambridge, MA) is a novel inhibitor of the proteasome. The proteasome plays a critical role in the degradation and, therefore, regulation of many proteins involved in cell cycle regulation, apoptosis, and angiogenesis. Bortezomib inhibits the growth of lung cancer cell lines in vitro and in vivo in athymic nude mouse xenografts. Bortezomib produces a G(2)-M arrest, increases in cyclin A and cyclin B, increases in p21, and increases apoptosis in these preclinical models. Phase I studies established that a dose of 1.4 mg/m(2) given i.v. on days 1, 4, 8, and 11 of a 3-week cycle produced acceptable toxicity and serum levels that resulted in proteasome inhibition. Phase II studies showed high-response rates in refractory multiple myeloma. These response rates were sufficiently high to allow accelerated approval of bortezomib by the Food and Drug Administration for this indication. Phase II trials in both non-small cell lung cancer and small cell lung cancer are in progress. A number of Phase I combination studies are also underway. Hopefully, bortezomib will show sufficient activity in lung cancer to improve survival in this dread disease.
References
Sep 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M PalmerM Koch
Sep 30, 1998·British Journal of Haematology·J BladéD Vesole
Oct 23, 2002·Proceedings of the National Academy of Sciences of the United States of America·Nicholas MitsiadesKenneth C Anderson
Nov 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiSteven L Soignet
May 10, 2003·Cancer Treatment Reviews·Paul Richardson
Jan 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy B DavisWalter M Stadler
Citations
Mar 11, 2006·Apoptosis : an International Journal on Programmed Cell Death·M LauricellaG Tesoriere
Aug 18, 2010·Molecular Cancer Therapeutics·Alykhan S NagjiDavid R Jones
Jan 22, 2009·PloS One·Karen Mruk, William R Kobertz
May 25, 2006·Current Opinion in Oncology·Manon S A BoddaertHerbert M Pinedo
Nov 24, 2004·Clinical Lung Cancer·Kesava G Reddy
Oct 22, 2008·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Subhankar Paul
Sep 16, 2006·Biochemical Pharmacology·Sabine OlivierVincent Bours
Apr 19, 2005·Hematology/oncology Clinics of North America·Olwen Hahn, Ravi Salgia
Nov 26, 2002·Seminars in Hematology·Razelle KurzrockHagop Kantarjian
Mar 6, 2012·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Ida PerrottaGiuseppe Donato
Apr 29, 2014·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Larissa PfistererThomas Korff
Jan 29, 2020·Cellular & Molecular Biology Letters·Qiang FanMing Xu
Feb 26, 2014·Physiological Research·T A BakerM Majetschak
Aug 4, 2006·Cancer Research·Izabela Młynarczuk-BiałyUlrike Seifert
Jun 17, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tarikere L GururajaDonald G Payan